# Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect

> **NCT02598596** · PHASE2 · COMPLETED · sponsor: **Ampel BioSolutions, LLC** · enrollment: 132 (actual)

## Conditions studied

- Gout

## Interventions

- **BIOLOGICAL:** Pegloticase
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT02598596
- **Lead sponsor:** Ampel BioSolutions, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2020-04-13
- **Final completion:** 2020-04-27
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2021-10-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02598596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02598596, "Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02598596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*